Invivyd to Participate at the Jefferies Healthcare Conference
01. Juni 2023 07:00 ET
|
Invivyd
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
11. Mai 2023 16:01 ET
|
Invivyd
Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from COVID-19 Initial data...
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
04. Mai 2023 16:01 ET
|
Invivyd
WALTHAM, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
25. April 2023 16:01 ET
|
Invivyd
WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
25. April 2023 07:00 ET
|
Invivyd
On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial being conducted in Australia, with cohort 1 dosing completeDiscussions are underway with the FDA and global...
Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
12. April 2023 07:00 ET
|
Invivyd
WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19
30. März 2023 16:01 ET
|
Invivyd
WALTHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
23. März 2023 16:01 ET
|
Invivyd
Advancing VYD222 into clinical development based on in vitro data demonstrating neutralizing activity against multiple important variants of concern, including XBB.1.5 Anticipate near-term...
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19
22. März 2023 16:30 ET
|
Invivyd
Research published online today in peer-reviewed journal Science Translational MedicineAnalysis of data from a Phase 2/3 COVID-19 prevention study (EVADE) of adintrevimab suggests clinically...
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
16. März 2023 07:00 ET
|
Invivyd
WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious...